Price (delayed)
$39.02
Market cap
$5.64B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.96
Enterprise value
$5.38B
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous
There are no recent dividends present for IMVT.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.